Vimarsana
Biggest News Aggregation in the World

Page 15 - Nasdaq Edit News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Nasdaq Edit. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Nasdaq Edit Today - Breaking & Trending Today

Editas Medicine Names Bernadette Connaughton to Board of - Vimarsana News

Editas Medicine Names Bernadette Connaughton to Board of

CAMBRIDGE, Mass., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it...

Editas Medicine Announces First Quarter 2021 Results and - Vimarsana News

Editas Medicine Announces First Quarter 2021 Results and

Advancing BRILLIANCE trial of EDIT-101 for LCA10; clinical data expected by year-end RUBY trial of EDIT-301 for sickle cell disease active and recruiting Preclinical ocular data presented at ARVO supports in vivo gene editing $723 million as of March 31, 2021 CAMBRIDGE, Mass., May 05, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today reported business highlights and financial results for the first quarter of 2021. “Our team is making tremendous progress towards discovering, developing, and manufacturing novel genome editing medicine...

Editas Medicine Names Mark S. Shearman, Ph.D., as Chief - Vimarsana News

Editas Medicine Names Mark S. Shearman, Ph.D., as Chief

Editas Medicine Names Mark S. Shearman, Ph.D., as Chief Scientific Officer May 05, 2021 06:59 ET | Source: Editas Medicine, Inc. Editas Medicine, Inc. Cambridge, Massachusetts, UNITED STATES CAMBRIDGE, Mass., May 05, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it named Mark S. Shearman, Ph.D., as the Company’s Executive Vice President and Chief Scientific Officer. Dr. Shearman will join Editas Medicine in June 2021, and will lead drug discovery, research, and development f...

Editas Medicine Announces Appointment of James C. Mullen as Chief Executive Officer - Vimarsana News

Editas Medicine Announces Appointment of James C. Mullen as Chief Executive Officer

Editas Medicine Announces Appointment of James C. Mullen as Chief Executive Officer Cindy Collins to Step Down Effective February 15, 2021 February 08, 2021 08:00 ET | Source: Editas Medicine, Inc. Editas Medicine, Inc. Cambridge, Massachusetts, UNITED STATES CAMBRIDGE, Mass., Feb. 08, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that James (Jim) C. Mullen will succeed Cynthia (Cindy) Collins as Chief Executive Officer, effective February 15, 2021. Mr. Mullen will cont...

Editas Medicine Announces Pricing of Offering of Common Stock - Vimarsana News

Editas Medicine Announces Pricing of Offering of Common Stock

Editas Medicine Announces Pricing of Offering of Common Stock January 20, 2021 22:30 ET | Source: Editas Medicine, Inc. Editas Medicine, Inc. Cambridge, Massachusetts, UNITED STATES CAMBRIDGE, Mass., Jan. 20, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading gene editing company, today announced the pricing of an underwritten offering of 3,500,000 shares of its common stock at a public offering price of $66.00 per share, before deducting underwriter discounts and commissions and estimated offering expenses. Gross proceeds fr...